成人表面活性剂相关间质性肺疾病的肺移植结局：前行的首个证据
Lung transplantation outcome in adult surfactant-related interstitial lung disease: first evidence to move on.
作者信息
Manali Effrosyni D, Griese Matthias, Papiris Spyros A
机构信息
2nd Pulmonary Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
These authors contributed equally.
出版信息
ERJ Open Res. 2023 Nov 20;9(6). doi: 10.1183/23120541.00646-2023. eCollection 2023 Nov.
Abstract
摘要
https://bit.ly/3QxG73Z. （此为网址，无法准确完整翻译，保留原文）
相似文献
1
Lung transplantation outcome in adult surfactant-related interstitial lung disease: first evidence to move on.
ERJ Open Res. 2023 Nov 20;9(6). doi: 10.1183/23120541.00646-2023. eCollection 2023 Nov.
2
Clinical significance of radiological pleuroparenchymal fibroelastosis pattern in interstitial lung disease patients registered for lung transplantation: a retrospective cohort study.
Respir Res. 2018 Aug 30;19(1):162. doi: 10.1186/s12931-018-0860-6.
3
Outcome of lung transplantation for adults with interstitial lung disease associated with genetic disorders of the surfactant system.
ERJ Open Res. 2023 Nov 20;9(6). doi: 10.1183/23120541.00240-2023. eCollection 2023 Nov.
4
The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis.
Respir Res. 2024 Aug 27;25(1):325. doi: 10.1186/s12931-024-02897-w.
5
Lung transplantation for interstitial lung disease.
Eur Respir Rev. 2021 Aug 3;30(161). doi: 10.1183/16000617.0017-2021. Print 2021 Sep 30.
6
A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
Dan Med J. 2015 Apr;62(4):B5069.
7
The prevalence and burden of interstitial lung diseases in the USA.
ERJ Open Res. 2021 Feb 7;8(1). doi: 10.1183/23120541.00630-2021. eCollection 2022 Jan.
8
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Drugs. 2021 Apr;81(5):575-586. doi: 10.1007/s40265-021-01487-0. Epub 2021 Mar 25.
9
Interstitial lung abnormalities: do symptoms matter?
ERJ Open Res. 2023 Sep 25;9(5). doi: 10.1183/23120541.00502-2023. eCollection 2023 Sep.
10
Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights.
BMC Pulm Med. 2018 May 15;18(1):70. doi: 10.1186/s12890-018-0643-3.
本文引用的文献
1
Outcome of lung transplantation for adults with interstitial lung disease associated with genetic disorders of the surfactant system.
ERJ Open Res. 2023 Nov 20;9(6). doi: 10.1183/23120541.00240-2023. eCollection 2023 Nov.
2
Influence of De Novo Malignancies on Long-Term Survival after Lung Transplantation.
Cancers (Basel). 2023 Aug 7;15(15):4011. doi: 10.3390/cancers15154011.
3
Hypomorphic pathogenic variant in SFTPB leads to adult pulmonary fibrosis.
Eur J Hum Genet. 2023 Sep;31(9):1083-1087. doi: 10.1038/s41431-023-01413-w. Epub 2023 Jun 28.
4
ABCA3 Deficiency-Variant-Specific Response to Hydroxychloroquine.
Int J Mol Sci. 2023 May 3;24(9):8179. doi: 10.3390/ijms24098179.
5
Quantifying Functional Impairment of Variants Associated with Interstitial Lung Disease.
Int J Mol Sci. 2023 Apr 20;24(8):7554. doi: 10.3390/ijms24087554.
6
ABCA3-related interstitial lung disease beyond infancy.
Thorax. 2023 Jun;78(6):587-595. doi: 10.1136/thorax-2022-219434. Epub 2023 Feb 20.
7
2022 Update of indications and contraindications for lung transplantation in France.
Respir Med Res. 2023 Jun;83:100981. doi: 10.1016/j.resmer.2022.100981. Epub 2022 Nov 28.
8
Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective.
Diagnostics (Basel). 2022 Nov 23;12(12):2928. doi: 10.3390/diagnostics12122928.
9
European Respiratory Society statement on familial pulmonary fibrosis.
Eur Respir J. 2023 Mar 16;61(3). doi: 10.1183/13993003.01383-2022. Print 2023 Mar.
10
Gene Therapeutics for Surfactant Dysfunction Disorders: Targeting the Alveolar Type 2 Epithelial Cell.
Hum Gene Ther. 2022 Oct;33(19-20):1011-1022. doi: 10.1089/hum.2022.130.
Zotero 插件